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S14Accurate mediastinal staging is the hallmark of a good thoracic oncology program. Mediastinal lymph node
staging is important for prognostication and to guide the administration of neoadjuvant and adjuvant therapy.
In addition, accurate mediastinal staging is necessary for a fair comparison of different clinical studies. The
most important surgical advance in mediastinal lymph node staging in the past few years is transcervical staging,
by either sternal elevation or video-assisted mediastinoscopy. The present report summarizes the existing pub-
lished data evaluating such an approach. (J Thorac Cardiovasc Surg 2012;144:S14-7)Of the 3 elements constituting the TNM staging system, the
most difficult element to accurately determine clinically is
the nodal component. The reference standard for this com-
ponent of staging is anatomic surgical resection accompa-
nied by systematic lymph node dissection. Accurate
preoperative nodal staging can help avoid futile surgery
with its attendant mortality and morbidity. In addition, ac-
curate preresection staging could help select patients for
neoadjuvant therapy. Improvements in staging, particularly
integrated positron emission tomography/computed tomog-
raphy (CT) have helped this process significantly.1 How-
ever, the limited specificity associated with imaging
necessitates invasive staging for histologic confirmation.
Thus, endoscopic ultrasound-guided fine needle aspiration2
represents a significant clinical advance. Although endo-
scopic staging offers a minimally invasive approach, the
false-negative rate is high enough to warrant more invasive
surgical staging when such testing is negative, especially in
clinical situations in which the probability of nodal spread is
high. Also, endoscopic staging does not perform well for re-
staging after neoadjuvant therapy. Thus, even with these ad-
vances, surgical preresection staging has a role in the
management of lung cancer. The traditional method for sur-
gical preresection staging of lung cancer has been mediasti-
noscopy. During the past few years, modifications of
mediastinoscopy have been evaluated to enable systematic
lymph node dissection, instead of sampling, to improve
on the accuracy of transcervical surgical mediastinal
staging. The 2 principal techniques that have evolved are
transcervical extended mediastinal lymphadenectomy
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The Journal of Thoracic and Cardiovascular Surglymphadenectomy (VAMLA). The most important studies
evaluating these approaches are summarized in Table 1.
TRANSCERVICAL EXTENDED MEDIASTINAL
LYMPHADENECTOMY
TEMLA extends traditional cervical mediastinoscopy
using sternal elevation and video mediastinoscopy. All ex-
isting published reports of this technique have been from
a single center in Zakopane, Poland. Detailed technical re-
ports of this approach have been published both in manu-
script form3 and as on-line videos (available from: http://
mmcts.ctsnetjournals.org/cgi/content/full/2006/1009/mmcts.
2005.001693 and http://www.ctsnet.org/sections/clinical
resources/thoracic/expert_tech-44.html). The approach
starts with a cervical collar incision akin to that for thyroid-
ectomy. Superior and inferior subplatysmal flaps are raised.
Bilateral recurrent laryngeal nerves are identified. A sternal
lift is performed with a retractor to create space. A plane of
dissection is established over the innominate artery, and the
right paratracheal space is dissected out by direct visualiza-
tion. Next, a pretracheal plane of dissection is established to
dissect out the subcarinal space. The left paratracheal space
is dissected after identification of the left recurrent
laryngeal nerve, again by direct visualization. The aortopul-
monary lymph node packet is then accessed after mobiliza-
tion of the brachiocephalic vein. Using this procedure,
levels 2L, 4L, 2R, 4R, 7, 8, 5, and 6 can be dissected. An
initial large report of this procedure in 256 patients demon-
strated excellent staging results with an accuracy of 98% in
a patient population with a disease prevalence of stage N2-
N3 of 31.3%. The most frequent significant complication
was recurrent laryngeal nerve injury, occurring in 2.3%
of patients but permanent in only 0.8%.4 A head-to-head
comparison of TEMLA with mediastinoscopy revealed
significantly better sensitivity for TEMLA than for media-
stinoscopy.5 In that small study, 41 patients were random-
ized to TEMLA vs mediastinoscopy, with TEMLA
revealing metastatic disease in 7 patients and mediastino-
scopy revealing metastatic disease in 3 patients. However,
the results of mediastinoscopy in that study were much
poorer than those reported by others.6 The accuracy of
TEMLA in restaging disease after neoadjuvant therapyery c September 2012
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CT ¼ computed tomography
EBUS ¼ endobronchial ultrasound
TEMLA ¼ transcervical extended mediastinal
lymphadenectomy
VAMLA ¼ video-assisted mediastinal
lymphadenectomyTABLE
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NPV, negatiagain demonstrated stellar results, with a sensitivity of
95.5% and negative predictive value of 97.4%.7 In the
study by Zielinski and colleagues,7 the overall rate of find-
ing unexpected N3 disease was 3 of 63 patients. These re-
sults are better than any other method of restaging short
of surgical resection. An indirect comparison of endobron-
chial ultrasound (EBUS)-fine needle aspiration with
TEMLA for restaging was published by Szlubowski and
colleagues.8 In their study, patients underwent restaging
with EBUS-fine needle aspiration. Those who were disease
negative on EBUS then underwent TEMLA for restaging;
15% of patients with EBUS-negative findings had positive
disease found using TEMLA. Despite only a sensitivity of
67%, the investigators concluded that surgical restaging
was not mandatory with negative EBUS findings in this
setting.8VIDEO-ASSISTED MEDIASTINAL
LYMPHADENECTOMY
VAMLA uses a mediastinoscope that can be attached to
a camera that displays the image on a video monitor. In
addition, the blades of the mediastinoscope used can be
spread along the axis of the handle, as well as at the tip,
to create a wider space for dissection. The additional
room enables bimanual dissection of lymph nodes similar
to a video-assisted thoracic surgery approach. The methodary of studies of TEMLA/VAMLA
Approach Patients (n) Compared with
VAMLA 46 Thoracotomy
VAMLA 23 Thoracotomy (n ¼ 18)
VAMLA 144 Thoracotomy (n ¼ 130)
VAMLAþVATS 18 VATS
VAMLA 108 VATS resection (n ¼ 97)
TEMLA 256 Thoracotomy (n ¼ 138)
TEMLA 21 Mediastinoscopy (n ¼ 20
TEMLA 63 Thoracotomy (n ¼ 42)
al extended mediastinal lymphadenectomy; VAMLA, video-assisted m
ve predictive value.
The Journal of Thoracic and Cawas pioneered by Hurtgen and colleagues.9 In an initial re-
port of 46 patients, excellent diagnostic accuracy was re-
ported, with 1 recurrent laryngeal nerve injury. A
follow-up publication by the same group of 144 patients
reported continued excellent staging accuracy. However,
5 recurrent laryngeal nerve injuries were reported. When
the lung resection was performed in a staged fashion,
marked scarring with difficult re-exploration was noted
in 19.2% of these patients. Of these, 9 patients received
neoadjuvant therapy. In this subset, the procedure was
not possible in 2 patients because of the significant scar-
ring and persistent bulky disease. An independent group
also reported their experience with VAMLA in 108 pa-
tients with a strategy of concomitant thoracoscopic resec-
tion.10 No additional lymph nodes were identified by
video-assisted thoracic surgery after VAMLA. In their se-
ries too, the main complication of VAMLA was recurrent
laryngeal nerve injury in 5 patients.INITIAL ROSWELL EXPERIENCE
We adopted TEMLA for patients with a high probability
of having nodal disease, including those with large tumors,
locally advanced tumors, or resection after neoadjuvant
therapy. Unlike previous reports, TEMLA was performed
at the same time as definitive resection, provided the frozen
section analysis report was negative for N2 disease. Patients
with extensive calcific atherosclerotic disease of the innom-
inate artery or patients with previous neck surgery (includ-
ing previous mediastinoscopy) were not chosen. The
outcomes and nodal harvest were measured. In cases in
which the nodes from a large dissected nodal packet were
not counted, the volume of the sample was measured, and
the nodal count was estimated at 1 node/0.5 cm3. TEMLA
was attempted on 19 patients and was successfully per-
formed on 18, with 1 technical failure owing to severe adhe-
sions. Of the 18 procedures, 1 was performed for metastaticPerformance characteristics Side effects
FNR 0% 1 recurrent laryngeal nerve injury
FNR 0% Blood loss>100 mL in 12%
FNR 0.9%, sensitivity 100%,
specificity 93.8%
Recurrent laryngeal nerve injury
3.4% patients
More stations and more lymph
nodes harvested by VAMLAþ
VATS
No difference
FNR 0% Recurrent laryngeal nerve injury
in 4.6% patients
FNR 2.8% Recurrent laryngeal nerve palsy
2.3%
) NPVof TEMLA 100% vs
mediastinoscopy 66.7%
Operative time and pain intensity
greater in TEMLA
NPVof TEMLA 97.4%
ediastinal lymphadenectomy; FNR, false-negative rate; VATS, video-assisted thoracic
rdiovascular Surgery c Volume 144, Number 3 S15
TABLE 2. Tumor characteristics and outcomes of patient undergoing
TEMLA at Roswell Park Cancer Institute
Variable Measure
Total patients (n) 19
Technical success rate (n) 18/19 (94.7)
Pathologic finding (n)
Metastatic thyroid cancer 1/19
Lung cancer 18/19
Length of stay (d)
ICU
Median 1
Range 0–16
Hospital
Median 1
Range 0–31
Atrial fibrillation 1/18 (8.3)
Patients with concomitant lung resection 15/17 (88.2)
Pneumonia/ARDS 2/18 (16.7)
Confusion 1/18 (8.3)
Tumor characteristics
Neoadjuvant therapy 12/17 (70.6)
Tumor involving chest wall 1/17 (5.9)
Tumors>6 cm 2/17 (11.8)
Lymph node harvest (n)
2R
Median 2
Range 0–6
4R
Median 4
Range 0–14
2L
Median 0
Range 0–3
4L
Median 2
Range 0–19
7
Median 4.5
Range 1–16
Data in parentheses are percentages. TEMLA, Transcervical extended mediastinal
lymphadenectomy; ICU, intensive care unit; ARDS, acute respiratory distress syn-
drome.
Session I: Lung Cancer Diagnosis and Staging Yendamuri and Demmythyroid cancer and the rest for lung cancer. Of those 17 pa-
tients, 12 (70.6%) had received neoadjuvant chemotherapy.
The median intensive care unit and hospital length of stay
was 1 and 5 days, respectively. No TEMLA-related compli-
cations occurred, including recurrent laryngeal nerve injury.
Of the 17 patients, 15 (88.2%) also underwent concomitant
surgical resection. The lymph node harvest data are listed in
Table 2. A technical observation made during the conduct of
these procedures was that the TEMLA procedure simplifies
the dissection of the main pulmonary artery from the main-
stem bronchus, the critical step in thoracoscopic pneumo-
nectomy because a part of the dissection is completed
during TEMLA. In addition, we now use electromyo-
graphic monitoring (requires avoidance of muscle relaxa-
tion), already routine for many thyroid operations, to help
identify and demonstrate preservation of the recurrent
nerves at TEMLA completion. This is especially useful to
distinguish TEMLA-related nerve dysfunction from any
transthoracic dissection related injury.
SHOULD VAMLA/TEMLA BE THE NEW
STANDARD?
From published data, it is clear that preresection staging is
accomplished most accurately using TEMLA or VAMLA
compared to any other preresection investigation. However,
this accuracy comes at a price—themost significant ofwhich
is recurrent laryngeal nerve injury. The current published
data suggest a 1% rate of injury with TEMLA and a 3% to
5% rate of injury with VAMLA; however, this is in expert
hands. It remains to be seenwhether this accuracy can be rep-
licated by other centers, because most data presented has
been from only a few centers. If the safety and accuracy
are replicable, surgeons should integrate this technology
with their current practice philosophy. The yield of surgical
mediastinal staging in the setting of a small peripheral lung
cancer with no suggestion of mediastinal positivity by CT
or positron emission tomography–CT scan is too low to jus-
tify the risk of TEMLA or VAMLA.11 Therefore, it is likely
that this procedure will be adopted in situations that have
a greater yield, just aswe have done in our practice. These in-
clude larger tumors, central tumors, and tumors with a high
uptake on positron emission tomography–CT. The inclusion
of larger tumors in this decision rubric is supported by at least
a few retrospective studies.12,13 However, 1 situation in
which the argument for TEMLA/VAMLA to be the new
standard of care is cogent is in restaging after neoadjuvant
therapy. In this situation, if one believes that residual
mediastinal disease precludes surgical resection, these
methods will be superior to all other restaging methods and
have a high potential for avoiding futile surgery.
A related, although different, question is the effect that
such restaging might have on the overall outcome of pa-
tients with NSCLC. It might be a reasonable to consider
disease detected by a larger operation such as TEMLAS16 The Journal of Thoracic and Cardiovascular Surgto be less relevant than that found by mediastinoscopy.
This difficult question would take a large randomized clin-
ical trial to answer and is unlikely to occur. In addition, no
data are available that prove an improvement in locore-
gional recurrence rates with these extensive mediastinal
staging procedures compared with endoscopic staging or
mediastinoscopy.CONCLUSIONS
TEMLA and VAMLA are improvements in conventional
mediastinoscopy with excellent accuracy. The wider adop-
tion of these procedures by the thoracic surgical community
will help determine the reproducibility of the safety and ac-
curacy data published thus far. If reproducible, TEMLA andery c September 2012
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